[go: up one dir, main page]

CY1108552T1 - Θεραπευτικη αντιμετωπιση της μη αλκοολικης στεατοηπατιτιδας (nash) - Google Patents

Θεραπευτικη αντιμετωπιση της μη αλκοολικης στεατοηπατιτιδας (nash)

Info

Publication number
CY1108552T1
CY1108552T1 CY20081100842T CY081100842T CY1108552T1 CY 1108552 T1 CY1108552 T1 CY 1108552T1 CY 20081100842 T CY20081100842 T CY 20081100842T CY 081100842 T CY081100842 T CY 081100842T CY 1108552 T1 CY1108552 T1 CY 1108552T1
Authority
CY
Cyprus
Prior art keywords
nash
alcoholic
steathepatidas
therapeutic
therapeutic treatment
Prior art date
Application number
CY20081100842T
Other languages
English (en)
Inventor
Deventer Sander Jan Hendrik Van
Original Assignee
Amsterdam Molecular Therapeutics B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amsterdam Molecular Therapeutics B.V. filed Critical Amsterdam Molecular Therapeutics B.V.
Publication of CY1108552T1 publication Critical patent/CY1108552T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01034—Lipoprotein lipase (3.1.1.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε μια μέθοδο για την θεραπευτική αντιμετώπιση της μη αλκοολικής στεατοηπατίτιδας (NASH) σε ένα άτομο διαμέσου της χορήγησης μιας αποτελεσματικής ποσότητας ενός θεραπευτικού μέσου λιποπρωτεϊνικής λιπάσης (LPL) στο άτομο. Το θεραπευτικό μέσο LPL είναι πλεονεκτικά μια πρωτεΐνη S447X ή ένα παράγωγο ή μια παραλλαγή αυτής, ή ένα νουκλεϊνικό οξύ το οποίο κωδικοποιεί μια τέτοια πρωτεΐνη. Το θεραπευτικό μέσο LPL δύναται να χρησιμοποιηθεί σε έναν φορέα γονιδιακής θεραπείας.
CY20081100842T 2004-06-21 2008-08-11 Θεραπευτικη αντιμετωπιση της μη αλκοολικης στεατοηπατιτιδας (nash) CY1108552T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58090304P 2004-06-21 2004-06-21
EP20050753069 EP1761273B1 (en) 2004-06-21 2005-06-20 Treatment of non alcoholic steatotic hepatitis (nash)

Publications (1)

Publication Number Publication Date
CY1108552T1 true CY1108552T1 (el) 2014-04-09

Family

ID=34970452

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100842T CY1108552T1 (el) 2004-06-21 2008-08-11 Θεραπευτικη αντιμετωπιση της μη αλκοολικης στεατοηπατιτιδας (nash)

Country Status (16)

Country Link
US (2) US20080280823A1 (el)
EP (1) EP1761273B1 (el)
JP (1) JP2008503569A (el)
KR (1) KR20070057712A (el)
CN (1) CN1972709A (el)
AT (1) ATE395073T1 (el)
AU (1) AU2005253897B2 (el)
CA (1) CA2568643A1 (el)
CY (1) CY1108552T1 (el)
DE (1) DE602005006809D1 (el)
DK (1) DK1761273T3 (el)
ES (1) ES2306163T3 (el)
PL (1) PL1761273T3 (el)
PT (1) PT1761273E (el)
SI (1) SI1761273T1 (el)
WO (1) WO2005123117A1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2328446T5 (es) 2000-02-04 2014-02-27 Children's Hospital Research Foundation Uso de lipasa ácida lisosomal para tratar la aterosclerosis y enfermedades asociadas
WO2007030375A2 (en) * 2005-09-08 2007-03-15 Children's Hospital Medical Center Lysosomal acid lipase therapy for nafld and related diseases
WO2010134806A1 (en) * 2009-05-18 2010-11-25 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Use of lipoprotein lipase (lpl) in therapy
CN102628060A (zh) * 2012-03-22 2012-08-08 北京济福霖生物技术有限公司 一种低脂奶的生产方法
MA41035A (fr) * 2014-08-19 2017-08-15 Shire Human Genetic Therapies Lipoprotéine lipase pour le traitement d'affections liées à une hypertriglycéridémie, y compris la pancréatite aiguë
CN115109788A (zh) * 2021-03-23 2022-09-27 北京锦篮基因科技有限公司 Aav介导的人脂蛋白脂酶肝脏异位表达载体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2311464T3 (es) * 1999-06-24 2009-02-16 The University Of British Columbia Terapia con variante de lipoproteina lipasa (lpl).
FR2795832B1 (fr) * 1999-06-30 2004-06-18 Plastic Omnium Valeo Interiors Dispositif de commande d'actionneur notamment pour vehicule
AU2001268149B2 (en) * 2000-06-01 2005-08-18 University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors

Also Published As

Publication number Publication date
KR20070057712A (ko) 2007-06-07
DE602005006809D1 (de) 2008-06-26
US20080280823A1 (en) 2008-11-13
AU2005253897A1 (en) 2005-12-29
AU2005253897B2 (en) 2011-09-01
PT1761273E (pt) 2008-10-28
ES2306163T3 (es) 2008-11-01
PL1761273T3 (pl) 2008-10-31
JP2008503569A (ja) 2008-02-07
CA2568643A1 (en) 2005-12-29
US20110081332A1 (en) 2011-04-07
EP1761273A1 (en) 2007-03-14
WO2005123117A1 (en) 2005-12-29
CN1972709A (zh) 2007-05-30
EP1761273B1 (en) 2008-05-14
SI1761273T1 (sl) 2008-10-31
DK1761273T3 (da) 2008-08-04
ATE395073T1 (de) 2008-05-15

Similar Documents

Publication Publication Date Title
CY1108552T1 (el) Θεραπευτικη αντιμετωπιση της μη αλκοολικης στεατοηπατιτιδας (nash)
DK1599575T3 (da) Fremgangsmåder til anvendelse af adipøst vævs-afledte celler i behandlingen af kardiovaskulære tilstande
NO20054958L (no) Substitulerte aminokarboksylsyrer
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
WO2006023544A3 (en) Therapeutic uses of inhibitors of rtp801
ATE390416T1 (de) Heterozyklische beta-aminoverbindungen als inhibitoren des dipeptidylpeptidase zur behandlung bzw. prevention von diabetes
ATE447574T1 (de) 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
NO20054769L (no) Substituerte fenylalkansyrer
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
MX2021006253A (es) Terapias génicas para enfermedad neurodegenerativa.
MX2007004841A (es) Triazoles utiles como inhibidores de proteinas cinasas.
EA201001749A1 (ru) Способ лечения недифференцированного артрита
WO2004019893A3 (en) Modulators of angiogenesis
EP1758998A4 (en) OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF IN THE TREATMENT OF FIBROUS CONDITIONS AND OTHER DISEASES
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой
ATE546155T1 (de) Verfahren zur stabilisierung eines kryopräzipitats von plasmatischen proteinen für eine wärmebehandlung zur viralen inaktivierung
ATE536745T1 (de) Zusammensetzung mit arazym zur prävention und behandlung von krebs
TW200806293A (en) Methods of treatment with CETP inhibitors
ATE365807T1 (de) Hepatitis b virus vektoren für gentherapie
ATE511401T1 (de) Kombinierte gentherapie zur behandlung makroskopischer glioma
ATE461693T1 (de) Verfahren zur behandlung von akuten rhinosinusitis
WO2010065536A3 (en) Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases
EA201170127A1 (ru) АНТАГОНИСТЫ РНК, НАЦЕЛЕННЫЕ НА Hsp27
MX357770B (es) Ácidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cáncer.